-
1
-
-
65749120107
-
Autoimmune disorders of the neuromuscular junction
-
Lang B, Vincent A. Autoimmune disorders of the neuromuscular junction. Curr Opin Pharmacol 2009;9:336-40.
-
(2009)
Curr Opin Pharmacol
, vol.9
, pp. 336-340
-
-
Lang, B.1
Vincent, A.2
-
2
-
-
80051548728
-
National surveillance of myasthenia gravis 2006 - An interim report
-
Murai H, Ochi H, Yoshikawa H, et al. National surveillance of myasthenia gravis 2006 - an interim report. Annual Report of Research Committee on Neuroimmunological Diseases of the Ministry of Health, Labour and Welfare of Japan, 2007:139-43.
-
(2007)
Annual Report of Research Committee on Neuroimmunological Diseases of the Ministry of Health, Labour and Welfare of Japan
, pp. 139-143
-
-
Murai, H.1
Ochi, H.2
Yoshikawa, H.3
-
3
-
-
33746534220
-
Guidelines for the treatment of autoimmune neuromuscular transmission disorders
-
DOI 10.1111/j.1468-1331.2006.01476.x
-
Skeie GO, Apostolski S, Evoli A, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006;13:691-9. (Pubitemid 44139369)
-
(2006)
European Journal of Neurology
, vol.13
, Issue.7
, pp. 691-699
-
-
Skeie, G.O.1
Apostolski, S.2
Evoli, A.3
Gilhus, N.E.4
Hart, I.K.5
Harms, L.6
Hilton-Jones, D.7
Melms, A.8
Verschuuren, J.9
Horge, H.W.10
-
4
-
-
4644371955
-
Treatment and outcome of myasthenia gravis: Retrospective multi-center analysis of 470 Japanese patients, 1999-2000
-
DOI 10.1016/j.jns.2003.09.016, PII S0022510X04001819
-
Kawaguchi N, Kuwabara S, Nemoto Y, et al. Treatment and outcome of myasthenia gravis: retrospective multi-center analysis of 470 Japanese patients, 1999-2000. J Neurol Sci 2004;224:43-7. (Pubitemid 39278261)
-
(2004)
Journal of the Neurological Sciences
, vol.224
, Issue.1-2
, pp. 43-47
-
-
Kawaguchi, N.1
Kuwabara, S.2
Nemoto, Y.3
Fukutake, T.4
Satomura, Y.5
Arimura, K.6
Osame, M.7
Hattori, T.8
-
5
-
-
14944344922
-
A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids
-
DOI 10.1093/qjmed/hci029
-
van Staa TP, Geusens P, Pols HA, et al. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 2005;98:191-8. (Pubitemid 40361316)
-
(2005)
QJM - Monthly Journal of the Association of Physicians
, vol.98
, Issue.3
, pp. 191-198
-
-
Van Staa, T.-P.1
Geusens, P.2
Pols, H.A.P.3
De Laet, C.4
Leufkens, H.G.M.5
Cooper, C.6
-
6
-
-
2142643786
-
Oral glucocorticoid use is associated with an increased risk of fracture
-
DOI 10.1007/s00198-003-1548-3
-
Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 2004;15:323-8. (Pubitemid 38543952)
-
(2004)
Osteoporosis International
, vol.15
, Issue.4
, pp. 323-328
-
-
Steinbuch, M.1
Youket, T.E.2
Cohen, S.3
-
7
-
-
20944440967
-
Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004)
-
DOI 10.1007/s00774-004-0596-x
-
Nawata H, Soen S, Takayanagi R, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 2005;23:105-9. (Pubitemid 40591032)
-
(2005)
Journal of Bone and Mineral Metabolism
, vol.23
, Issue.2
, pp. 105-109
-
-
Nawata, H.1
Soen, S.2
Takayanagi, R.3
Tanaka, I.4
Takaoka, K.5
Fukunaga, M.6
Matsumoto, T.7
Suzuki, Y.8
Tanaka, H.9
Fujiwara, S.10
Miki, T.11
Sagawa, A.12
Nishizawa, Y.13
Seino, Y.14
-
8
-
-
33745112635
-
Population-based assessment of adverse events associated with long-term glucocorticoid use
-
DOI 10.1002/art.21984
-
Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006;55:420-6. (Pubitemid 43887028)
-
(2006)
Arthritis Care and Research
, vol.55
, Issue.3
, pp. 420-426
-
-
Curtis, J.R.1
Westfall, A.O.2
Allison, J.3
Bijlsma, J.W.4
Freeman, A.5
George, V.6
Kovac, S.H.7
Spettell, C.M.8
Saag, K.G.9
-
9
-
-
0031081658
-
FK506 prevents induction of rat experimental autoimmune myasthenia gravis
-
DOI 10.1006/jaut.1996.0111
-
Yoshikawa H, Iwasa K, Satoh K, et al. FK506 prevents induction of rat experimental autoimmune myasthenia gravis. J Autoimmun 1997;10:11-16. (Pubitemid 27110303)
-
(1997)
Journal of Autoimmunity
, vol.10
, Issue.1
, pp. 11-16
-
-
Yoshikawa, H.1
Iwasa, K.2
Satoh, K.3
Takamori, M.4
-
10
-
-
0242331696
-
Clinical study of FK506 in patients with myasthenia gravis
-
DOI 10.1002/mus.10472
-
Konishi T, Yoshiyama Y, Takamori M, et al. Clinical study of FK506 in patients with myasthenia gravis. Muscle Nerve 2003;28:570-4. (Pubitemid 37339910)
-
(2003)
Muscle and Nerve
, vol.28
, Issue.5
, pp. 570-574
-
-
Konishi, T.1
Yoshiyama, Y.2
Takamori, M.3
Yagi, K.4
Mukai, E.5
Saida, T.6
-
11
-
-
14544303623
-
Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus)
-
DOI 10.1136/jnnp.2004.042176
-
Konishi T, Yoshiyama Y, Takamori M, et al. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry 2005;76:448-50. (Pubitemid 40299146)
-
(2005)
Journal of Neurology, Neurosurgery and Psychiatry
, vol.76
, Issue.3
, pp. 448-450
-
-
Konishi, T.1
Yoshiyama, Y.2
Takomori, M.3
Saido, T.4
-
12
-
-
4344609125
-
Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis
-
Kawaguchi N, Yoshiyama Y, Nemoto Y, et al. Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr Med Res Opin 2004;20:1269-73. (Pubitemid 39120791)
-
(2004)
Current Medical Research and Opinion
, vol.20
, Issue.8
, pp. 1269-1273
-
-
Kawaguchi, N.1
Yoshiyama, Y.2
Nemoto, Y.3
Munakata, S.4
Fukutake, T.5
Hattori, T.6
-
13
-
-
20844451899
-
Efficacy of low-dose FK506 in the treatment of myasthenia gravis - A randomized pilot study
-
DOI 10.1159/000085833
-
Nagane Y, Utsugisawa K, Obara D, et al. Efficacy of low-dose FK506 in the treatment of Myasthenia gravis - a randomized pilot study. Eur Neurol 2005;53:146-50. (Pubitemid 40864306)
-
(2005)
European Neurology
, vol.53
, Issue.3
, pp. 146-150
-
-
Nagane, Y.1
Utsugisawa, K.2
Obara, D.3
Kondoh, R.4
Terayama, Y.5
-
14
-
-
18144429444
-
Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis
-
DOI 10.1212/01.WNL.0000160392.32894.6D
-
Ponseti JM, Azem J, Fort JM, et al. Long-term results of tacrolimus in cyclosporine-and prednisone-dependent myasthenia gravis. Neurology 2005;64:1641-3. (Pubitemid 40617711)
-
(2005)
Neurology
, vol.64
, Issue.9
, pp. 1641-1643
-
-
Ponseti, J.M.1
Azem, J.2
Fort, J.M.3
Lopez-Cano, M.4
Vilallonga, R.5
Buera, M.6
Cervera, C.7
Armengol, M.8
-
15
-
-
0034641222
-
Myasthenia gravis: Recommendations for clinical research standards
-
Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America
-
Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23.
-
(2000)
Neurology
, vol.55
, pp. 16-23
-
-
Jaretzki III, A.1
Barohn, R.J.2
Ernstoff, R.M.3
-
16
-
-
0020513595
-
Myasthenia gravis: Long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity
-
Besinger UA, Toyka KV, Homberg M, et al. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 1983;33:1316-21. (Pubitemid 13021194)
-
(1983)
Neurology
, vol.33
, Issue.10
, pp. 1316-1321
-
-
Besinger, U.A.1
Toyka, K.V.2
Homberg, M.3
-
17
-
-
44949109211
-
Steroids and immunosuppressant drugs in myasthenia gravis
-
DOI 10.1038/ncpneuro0810, PII NCPNEURO0810
-
Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract Neurol 2008;4:317-27. (Pubitemid 351803614)
-
(2008)
Nature Clinical Practice Neurology
, vol.4
, Issue.6
, pp. 317-327
-
-
Sathasivam, S.1
-
18
-
-
0027319951
-
A clinical therapeutic trial of cyclosporine in Myasthenia gravis
-
Tindall RS, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993;681:539-51. (Pubitemid 23233874)
-
(1993)
Annals of the New York Academy of Sciences
, vol.681
, pp. 539-551
-
-
Tindall, R.S.A.1
Phillips, J.T.2
Rollins, J.A.3
Wells, L.4
Hall, K.5
-
19
-
-
0025776560
-
The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1
-
Banerji SS, Parsons JN, Tocci MJ. The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. Mol Cell Biol 1991;11:4074-87. (Pubitemid 21895797)
-
(1991)
Molecular and Cellular Biology
, vol.11
, Issue.8
, pp. 4074-4087
-
-
Banerji, S.S.1
Parsons, J.N.2
Tocci, M.J.3
-
20
-
-
0032125633
-
Dexamethasone and triamcinolone acetonide accumulation in mouse fibroblasts is differently modulated by the immunosuppressants cyclosporin A, FK506, rapamycin and their analogues, as well as by other P-glycoprotein ligands
-
DOI 10.1016/S0960-0760(98)00008-9, PII S0960076098000089
-
Marsaud V, Mercier-Bodard C, Fortin D, et al. Dexamethasone and triamcinolone acetonide accumulation in mouse fibroblasts is differently modulated by the immunosuppressants cyclosporin A, FK506, rapamycin and their analogues, as well as by other P-glycoprotein ligands. J Steroid Biochem Mol Biol 1998;66:11-25. (Pubitemid 28335451)
-
(1998)
Journal of Steroid Biochemistry and Molecular Biology
, vol.66
, Issue.1-2
, pp. 11-25
-
-
Marsaud, V.1
Mercier-Bodard, C.2
Fortin, D.3
Le, B.S.4
Renoir, J.-M.5
-
21
-
-
13544267438
-
Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506
-
DOI 10.1021/bi048503v
-
Davies TH, Ning YM, Sanchez ER. Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. Biochemistry 2005;44:2030-8. (Pubitemid 40223631)
-
(2005)
Biochemistry
, vol.44
, Issue.6
, pp. 2030-2038
-
-
Davies, T.H.1
Ning, Y.-M.2
Sanchez, E.R.3
-
22
-
-
33846966655
-
P-glycoprotein function in peripheral blood mononuclear cells of myasthenia gravis patients treated with tacrolimus
-
Tanaka S, Hirano T, Saito T, et al. P-glycoprotein function in peripheral blood mononuclear cells of myasthenia gravis patients treated with tacrolimus. Biol Pharm Bull 2007;30:291-6.
-
(2007)
Biol Pharm Bull
, vol.30
, pp. 291-296
-
-
Tanaka, S.1
Hirano, T.2
Saito, T.3
-
23
-
-
0029085326
-
FK506 augments activation-induced programmed cell death of T lymphocytes in vivo
-
Migita K, Eguchi K, Kawabe Y, et al. FK506 augments activation-induced programmed cell death of T lymphocytes in vivo. J Clin Invest 1995;96:727-32.
-
(1995)
J Clin Invest
, vol.96
, pp. 727-732
-
-
Migita, K.1
Eguchi, K.2
Kawabe, Y.3
-
24
-
-
2442636414
-
Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis
-
Takamori M, Motomura M, Kawaguchi N, et al. Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology 2004;62:1894-6. (Pubitemid 38661763)
-
(2004)
Neurology
, vol.62
, Issue.10
, pp. 1894-1896
-
-
Takamori, M.1
Motomura, M.2
Kawaguchi, N.3
Nemoto, Y.4
Hattori, T.5
Yoshikawa, H.6
Otsuka, K.7
-
25
-
-
41949099206
-
Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis
-
Furukawa Y, Yoshikawa H, Iwasa K, et al. Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis. J Neuroimmunol 2008;195:108-15.
-
(2008)
J Neuroimmunol
, vol.195
, pp. 108-115
-
-
Furukawa, Y.1
Yoshikawa, H.2
Iwasa, K.3
|